Skip to main content

Paula Sowon Lee, MD

Paula Lee, MD
Assistant Professor of Obstetrics and Gynecology
Campus Mail: Box 3079 Med Ctr, Durham, NC 27710
Phone: (919) 684-3765
Email: paula.s.lee@duke.edu

Dr. Paula Lee is an Assistant Professor in the Division of Gynecologic Oncology at Duke University Medical Center.  She received her undergraduate degree in Biology and Asian Studies from the University of Michigan and graduated with a combined medical degree with a Masters in Public Health from Tulane University.  She completed her residency in Obstetrics and Gynecology and her fellowship in Gynecologic Oncology at Duke University Medical Center.  Upon completing her oncology fellowship in 2007, she accepted a faculty position within the Division of Gynecologic Oncology at Duke.

Her research interests include therapeutic and surgical trials for gynecologic malignancies and improving end of life care. She is board certified in Gynecologic Oncology and Hospice and Palliative Medicine. She has successfully mentored residents and fellows in their research and clinical endeavors. She is also involved in global health initiatives and has interests in developing a sustainable training program in gynecologic oncology in sub-saharan African countries. 

Education and Training

  • Residency, Ob/Gyn, Duke University, 2000 - 2004
  • M.D., Tulane University, 2000

Research

Research interests include therapeutic and surgical trials for gynecologic malignancies and improving end of life care.

Publications

Rimel, BJ, Burke, WM, Higgins, RV, Lee, PS, Lutman, CV, and Parker, L. "Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice." Gynecologic Oncology 137, no. 2 (January 1, 2015): 280-284.

Full Text

Campos, SM, Brady, WE, Moxley, KM, O'Cearbhaill, RE, Lee, PS, DiSilvestro, PA, Rotmensch, J, Rose, P, Thaker, PH, O'Malley, DM, ParvizHanjani, , Zuna, RE, and Hensley, ML. "Corrigendum to: A phase II evaluation of Pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group Study [Gynecol Oncol 133 (2014) 537–541]." Gynecologic Oncology 135, no. 3 (December 2014): 624-624.

Full Text

Havrilesky, LJ, Alvarez Secord, A, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (December 2014): 3651-3659.

Full Text

Powell, MA, Sill, MW, Goodfellow, PJ, Benbrook, DM, Lankes, HA, Leslie, KK, Jeske, Y, Mannel, RS, Spillman, MA, Lee, PS, Hoffman, JS, McMeekin, DS, and Pollock, PM. "A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology 135, no. 1 (October 1, 2014): 38-43.

Full Text

Powell, MA, Sill, MW, Goodfellow, PJ, Benbrook, DM, Lankes, HA, Leslie, KK, Jeske, Y, Mannel, RS, Spillman, MA, Lee, PS, Hoffman, JS, McMeekin, DS, and Pollock, PM. "A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study." Gynecologic oncology 135, no. 1 (October 2014): 38-43.

Full Text

Campos, SM, Brady, WE, Moxley, KM, O'Cearbhaill, RE, Lee, PS, DiSilvestro, PA, Rotmensch, J, Rose, PG, Thaker, PH, O'Malley, DM, Hanjani, P, Zuna, RE, and Hensley, ML. "A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study." Gynecologic oncology 133, no. 3 (June 2014): 537-541.

Full Text

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, S, Celia, D, Weinfurt, K, Abernethy, AP, and Reed, SD. "Relative influence of factors determining a woman's preference for treatment options in ovarian cancer." May 20, 2014.

Scholars@Duke

Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients." Gynecologic Oncology 133, no. 2 (May 2014): 211-215.

Full Text

Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients." Gynecologic oncology 133, no. 2 (May 2014): 211-215.

Full Text

Havrilesky, L, Secord, A, Ehrisman, J, Berchuck, A, Valea, F, Lee, P, Cella, D, Weinfurt, K, Abernethy, A, and Reed, S. "Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment." May 2014.

Full Text

Pages